What is Pleno?
Pleno Inc. operates at the intersection of biotechnology and advanced signal processing. Its core offering, the Hypercoding platform, is designed to deliver targeted biological information with unprecedented precision and performance. By applying telecommunications-grade signal processing to multi-omic data, the company addresses significant bottlenecks in current clinical testing workflows. This technological differentiation allows Pleno to provide researchers and clinicians with a scalable solution for complex biological analysis, effectively bridging the gap between raw data acquisition and actionable medical insights.
How much funding has Pleno raised?
Pleno has raised a total of $80M across 3 funding rounds:
Other Financing Round
$15M
Series A
$40M
Series B
$25M
Other Financing Round (2022): $15M with participation from Alexandria Venture Investments and Medical Excellence Capital
Series A (2022): $40M led by Foresite Capital and Deerfield Management
Series B (2024): $25M supported by Deerfield Management Group, Foresite Capital, and Medical Excellence Capital
Key Investors in Pleno
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
Medical Excellence Capital
Medical Excellence Capital (MEC) is an early-stage life sciences venture fund focused on advancing precision health innovations through precision capital. The firm combines experienced investment professionals with a proprietary national medical network to address complex medical challenges.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for Pleno?
With the successful closure of its latest financing round, Pleno is well-positioned to accelerate the commercial deployment of its multi-omic instrument platform. The strategic focus will likely shift toward expanding its footprint in clinical diagnostic markets and enhancing the throughput capabilities of its Hypercoding technology. As the company transitions into a more mature operational phase, the emphasis will remain on fostering strategic partnerships within the healthcare ecosystem to ensure its platform becomes a standard tool for precision health initiatives. Continued investment in data science and biological research will be paramount to maintaining its competitive advantage in the rapidly evolving life sciences sector.
See full Pleno company page
